Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions for an important protein, p53, in the pigmentation of skin. Fisher's study shows that in addition to its function as a tumor suppressor in other cancers in the body, p53 also plays a key role in prompting the skin to tan in response to ultraviolet light from the sun. By promoting tanning, p53 deters the development of the skin cancer melanoma, which is increasing in incidence faster than any other cancer in the world.

Fisher's research also shows that p53 causes the production of an endorphin after ultraviolet exposure, and this may modulate sensation in the skin in a manner that influences behaviors, possibly including sun-seeking behaviors.

For Magen BioSciences, the study in Cell provides important proof of concept for the company's approach to identify and develop therapeutic treatments for pigmentation disorders.

"We know that people who tan easily or have dark pigmentation are far less likely to develop melanoma," said David Fisher, with the Dana-Faber Cancer Institute. "This study suggests that p53, one of the best-known tumor-suppressor proteins in our body, goes into action when skin cells experience UV exposure, prompting the skin to tan as a defensive mechanism against DNA damage and at the same time creating endorphins that may alter sensation or even behavior."

"Dr. Fisher's discovery of this new function for a well-known protein sheds new light on the mechanism and function of tanning," said Brian Gallagher, Ph.D., Magen's president and chief executive officer. "This discovery will help Magen BioSciences identify lead compounds and develop therapeutic treatments for disfiguring dermato logical pigmentation disorders such as vitiligo, melasma, solar lentigos and post-inflammation hyperpigmentation."

About Magen BioSciences

Magen BioSciences is a specialty pharmaceutical company focused on developing proprietary medical therapies for the dermatology market. Magen was co-founded in March 2006 by Richard Aldrich, David Fisher, M.D. Ph.D., Phillip Sharp, Ph.D., David Shaw, Christopher Walsh, Ph.D. and Christoph Westphal, M.D., Ph.D. Investors include Alexandria Real Estate, ARCH Venture Partners, Highland Capital Partners, IDG Ventures, Lux Capital, QVT Financial LP, TVM Capital and Venrock Associates.

Contact

for Magen BioSciences, Inc.
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
www.magenbiosciences.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 PLAD, Inc. (OTC Pink: PLAD) is ... sales exceeding company targets, are adding key personnel to ... from the United States Patent and Trademark Office for ... Executive Officer of PLAD, Inc.  In January, PLAD established ... with two new customers, Cumberland Goodwill EMS ...
(Date:2/11/2016)... February 11, 2016 F ast ... answers at the ... provider of scientific, technical and medical information products and services, has launched ... peer reviewed clinical information via a mobile device. Elsevier designed the mobile ... Nursing. The new app is available in Android and ...
(Date:2/11/2016)... Ohio , Feb. 11, 2016  Community pharmacists ... increasing efficiency for the pharmacy through a custom-built medication ... Schieber , pharmacist and owner at Schieber Family ... "We can get a lot of patients enrolled in ... for everybody. It,s a win for the patient, and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
Breaking Medicine News(10 mins):